HealthcareMid capRs 14,972 crRs 80.0 cr traded a day
Close on 10 September 2026
330.40
+0.08%
52-week range97% of the way up
156.89335.90
Market cap
14,972 cr
P/E (TTM)
28.7×
industry 45×
EPS (TTM)
11.50
Revenue YoY
+35.6%
Q1 FY27
Profit YoY
+173.9%
Net margin
19.0%
+9.6pt vs a year ago
Growth trend
-1072.8pt
vs last quarter’s YoY
1 month
+5.7%
Below 52w high
1.7%
RSI (14)
57
Daily swing
3.8%
average true range
Volume
0.3×
vs 20-day average
Traded
Rs 80 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
Key metrics
each ranked against every stock scanned tonight
Above the 200-day average
Top of the universe
+51.6%
One-year return
Top of the universe
+89.6%
Return on capital employed
Top of the universe
22.6%
Debt to equity
Above the median
0.01×
Profitable quarters, last four
of the last four reported
4 of 4
Cash conversion
cash from operations against reported profit
88%
Revenue growth, year on year
latest reported quarter
+35.6%
Below the 52-week high
from the highest close of the year
-1.6%
1 week
−0.54%
1 month
+5.69%
3 months
+32.29%
6 months
+96.80%
1 year
+89.61%
The read
written from the numbers on this page
The evidence leans constructive9 supporting, 0 against, 0 worth knowing
Supporting
trading 52% above its 200-day average
sitting at 97% of its 52-week range, with little overhead supply from trapped buyers
up 90% over twelve months
matches profit that turns into cash, which has beaten the market by +2.73 points over 20 sessions across 9,184 past signals
11 of the scans it matches have a positive measured record
5 independent kinds of evidence agree today, which is uncommon
revenue grew 36% year on year in the quarter ending 30 June 2026
net margin has widened from 13.8% to 19.0% across four quarters
priced at 29× earnings against an industry median of 45× — 36% below its peers
Against
nothing the data supports either way
Worth knowing
nothing the data supports either way
What would change this read: a close below 218, its 200-day average; a failure to hold the top of its 52-week range.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
from the filings and from the price, with the figure behind every line
Working7
Net profit rose 173.9% year on year, from Rs 58 cr to Rs 159 cr.
+173.9%Rs 58 crRs 159 cr
Profit grew faster than revenue, +173.9% against +35.6%.
+173.9%+35.6%
Net margin moved from 9.4% to 19.0%.
9.4%19.0%
Trading 51.6% above its 200-day average, which is the line most investors use to separate a bull phase from a bear one.
+51.6%
Within 1.6% of its 52-week high.
-1.6%
Up 89.6% over the past year.
+89.6%
3 different kinds of evidence point at it tonight, not 3 versions of the same one.
3 families
Needs watching
Nothing on this side tonight — not in the filings and not in the price.
Every figure here is computed — from the company’s own filings, or from its own closing prices. Wording of 3 of these 3 filing lines was drafted by a language model, which is given the figures and may not introduce another — any sentence containing a number that did not come from the filings is discarded before it reaches this page.
How it has performed
price return over each window, beside the median NSE stock over the same days
What the scans say today
13 of 47 matched on 10 Sep
MARKSANS matches 13 of the 47 scans today, across 5 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
Return on capital uses profit before tax over equity plus borrowings. The textbook version adds finance costs back; those are not tagged reliably in quarterly filings, so this understates the ratio for a heavily borrowed company rather than flattering it. Balance sheets are filed half-yearly, so these can be up to six months behind the profit figures above.
Valuation against its own history
500 sessions since 26 September 2024
26×
median 30×
41×
now 29×
MARKSANS trades at 29× trailing earnings, close to its median of 30× over this window. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Other filing filings were typically +0.01pt vs the market over the next 5 sessions (n=17,202) · AGM / EGM filings were typically +0.17pt vs the market over the next 5 sessions (n=8,423) · Results filings were typically -0.51pt vs the market over the next 5 sessions (n=7,726)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 36% against the same quarter a year earlier
profit rose 174% year on year
net margin widened from 17.4% to 19.0%
revenue rose in 3 of the last 4 quarters
Going against it
nothing clear in the filed numbers
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
30 Jun · consolidated
841
207
159
3.47
19.0%
Q4 FY26
31 Mar · consolidated
856
200
149
3.27
17.4%
Q3 FY26
31 Dec · consolidated
754
151
114
2.50
15.1%
Q2 FY26
30 Sep · consolidated
720
133
99
2.17
13.8%
Q1 FY26
30 Jun · consolidated
620
77
58
1.29
9.4%
Q4 FY25
31 Mar · consolidated
71
12
9
2.00
12.8%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+13.3%
Versus 200-day average+51.6%
Below 52-week high-1.6%
Above 52-week low+110.6%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)56.6
Higher closes in last 53 of 5
Six-month return+96.80%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)3.85%
Volume versus 20-day0.3x
Median daily turnoverRs 80.0 cr
Peers
Healthcare · 68 classified companies
MARKSANS trades at 28.7× trailing earnings against an industry median of 44.7× across 65 other classified companies in its industry — cheaper than them, by 36%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.